Skip to main content

Table 2 Expression levels of SRD5A1 in NSCLC and NAT samples as measured by qRT-PCR.

From: 5-alpha-reductase type I (SRD5A1) is up-regulated in non-small cell lung cancer but does not impact proliferation, cell cycle distribution or apoptosis

Primer target

Analyzed biopsy

Number

of samples

Average Ct

Average

standard deviation

SRD5A1 #1

NAT

9

30.74

0.97

 

tumor

23

29.25

1.37

SRD5A1 #2

NAT

9

31.30

1.16

 

tumor

23

29.45

1.69

Cyclophilin

NAT

9

21.28

0.52

 

tumor

23

20.46

0.98

18S rRNA

NAT

9

16.94

0.56

 

tumor

23

17.01

0.67

  1. The analysis was performed on tumor samples from 23 patients, of which 9 provided NAT as well.